2423571
Project Grant
Overview
Grant Description
SBIR Phase I: Tissue specific delivery of payloads - The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is pivotal for the treatment of Inflammatory Bowel Disease (IBD), which affects around 3.1 million adults in the United States.
Traditional treatments are broad and often lead to severe side effects.
This project develops a targeted therapeutic delivery system intended to increase treatment precision and reduce adverse effects.
Specifically, it aims to provide relief for the 5-10% of patients unresponsive to existing treatments, opening a market opportunity estimated at $4.65 billion.
This technology is anticipated to advance the field of precision medicine by enabling therapies that specifically target diseased tissues, potentially improving treatment outcomes for a variety of chronic conditions beyond IBD, and paving the way for reduced healthcare costs and enhanced patient well-being.
This Small Business Innovation Research (SBIR) Phase I project is dedicated to creating a novel platform for identifying agents that can specifically accumulate in diseased tissues.
The primary goal is to develop a proof of concept showing that our platform can uncover agents capable of targeted delivery to the gastrointestinal tract.
This phase involves comprehensive testing in macaques, chosen for their physiological similarities to humans, to ensure the agents maintain their targeting ability without losing functionality.
Expected results include demonstrating that these agents can consistently localize to specific tissues in the gut.
Success in this phase will set the stage for Phase II, where these targeting agents will be paired with therapeutic compounds to test efficacy in improving treatment outcomes.
The project's completion will enable the company to engage with pharmaceutical companies for potential partnerships and to apply for further funding through an NIH SBIR Phase II project, focusing on enhanced therapeutic applications.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.
Subawards are planned for this award.
Traditional treatments are broad and often lead to severe side effects.
This project develops a targeted therapeutic delivery system intended to increase treatment precision and reduce adverse effects.
Specifically, it aims to provide relief for the 5-10% of patients unresponsive to existing treatments, opening a market opportunity estimated at $4.65 billion.
This technology is anticipated to advance the field of precision medicine by enabling therapies that specifically target diseased tissues, potentially improving treatment outcomes for a variety of chronic conditions beyond IBD, and paving the way for reduced healthcare costs and enhanced patient well-being.
This Small Business Innovation Research (SBIR) Phase I project is dedicated to creating a novel platform for identifying agents that can specifically accumulate in diseased tissues.
The primary goal is to develop a proof of concept showing that our platform can uncover agents capable of targeted delivery to the gastrointestinal tract.
This phase involves comprehensive testing in macaques, chosen for their physiological similarities to humans, to ensure the agents maintain their targeting ability without losing functionality.
Expected results include demonstrating that these agents can consistently localize to specific tissues in the gut.
Success in this phase will set the stage for Phase II, where these targeting agents will be paired with therapeutic compounds to test efficacy in improving treatment outcomes.
The project's completion will enable the company to engage with pharmaceutical companies for potential partnerships and to apply for further funding through an NIH SBIR Phase II project, focusing on enhanced therapeutic applications.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.
Subawards are planned for this award.
Awardee
Funding Goals
THE GOAL OF THIS FUNDING OPPORTUNITY, "NSF SMALL BUSINESS INNOVATION RESEARCH (SBIR)/ SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAMS PHASE I", IS IDENTIFIED IN THE LINK: HTTPS://WWW.NSF.GOV/PUBLICATIONS/PUB_SUMM.JSP?ODS_KEY=NSF23515
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
San Carlos,
California
94070-4002
United States
Geographic Scope
Single Zip Code
Eugit Therapeutics was awarded
Project Grant 2423571
worth $275,000
from National Science Foundation in August 2024 with work to be completed primarily in San Carlos California United States.
The grant
has a duration of 1 year and
was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.
The Project Grant was awarded through grant opportunity NSF Small Business Innovation Research / Small Business Technology Transfer Phase I Programs.
SBIR Details
Research Type
SBIR Phase I
Title
SBIR Phase I: Tissue specific delivery of payloads
Abstract
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is pivotal for the treatment of Inflammatory Bowel Disease (IBD), which affects around 3.1 million adults in the United States. Traditional treatments are broad and often lead to severe side effects. This project develops a targeted therapeutic delivery system intended to increase treatment precision and reduce adverse effects. Specifically, it aims to provide relief for the 5-10% of patients unresponsive to existing treatments, opening a market opportunity estimated at $4.65 billion. This technology is anticipated to advance the field of precision medicine by enabling therapies that specifically target diseased tissues, potentially improving treatment outcomes for a variety of chronic conditions beyond IBD, and paving the way for reduced healthcare costs and enhanced patient well-being.
This Small Business Innovation Research (SBIR) Phase I project is dedicated to creating a novel platform for identifying agents that can specifically accumulate in diseased tissues. The primary goal is to develop a proof of concept showing that our platform can uncover agents capable of targeted delivery to the gastrointestinal tract. This phase involves comprehensive testing in macaques, chosen for their physiological similarities to humans, to ensure the agents maintain their targeting ability without losing functionality. Expected results include demonstrating that these agents can consistently localize to specific tissues in the gut. Success in this phase will set the stage for Phase II, where these targeting agents will be paired with therapeutic compounds to test efficacy in improving treatment outcomes. The project’s completion will enable the company to engage with pharmaceutical companies for potential partnerships and to apply for further funding through an NIH SBIR Phase II project, focusing on enhanced therapeutic applications.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
BM
Solicitation Number
NSF 23-515
Status
(Complete)
Last Modified 8/27/24
Period of Performance
8/15/24
Start Date
7/31/25
End Date
Funding Split
$275.0K
Federal Obligation
$0.0
Non-Federal Obligation
$275.0K
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
2423571
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
Y8KZTTKGUXL5
Awardee CAGE
None
Performance District
CA-15
Senators
Dianne Feinstein
Alejandro Padilla
Alejandro Padilla
Modified: 8/27/24